RecruitingNCT07205341
Detecting Changes in Arterial Blood Volume and Cardiac Efficiency
A Pilot Clinical Study to Assess Correlation Between Arterial Blood Volume Status and Cardiac Efficiency, and HemoCept Device Data in Trans-Aortic Valve Replacement (TAVR} Surgery
Sponsor
HemoCept Inc.
Enrollment
20 participants
Start Date
Apr 29, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The objective of this Pilot Study is to demonstrate the efficacy of the Hemocept device in detecting changes in arterial blood volume and cardiac efficiency.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria6
- Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.
- Subjects can be any gender but must be between (and including) the ages of 18 and 80.
- Subject ls being treated by the participating healthcare facility .
- , Subject requires a trans-aortic valve replacement.
- Subject is able and willing to provide informed consent and HIPM authorization.
- Subject is able and willing to meet all study requirements.
Exclusion Criteria5
- Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
- Subject has a personal medical history that includes:
- Long O-T syndrome
- Cardiac channelopathies
- Seizures
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07205341
Related Trials
Patient Quality of Recovery After TAVR With Different Sedation Regimens
NCT075565231 location
Hydra Registry - UK
NCT065075794 locations
Hydra Registry - Italy Experience
NCT059566524 locations
Hydra Single-centre Experience - Copenhagen, Denmark
NCT063426351 location
Ischemic And Bleeding Risk Assessment After TAVR
NCT0600094312 locations